Crohn's Disease: key endpoint results by drug

The key endpoints of Crohn's Disease trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Crohn's Disease page.

Clinical remission (induction)

Clinical remission (induction) in Crohn's Disease: 12 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab37.3%6.8%+30.5160/80 mg · wk 4 · n 102NCT02499783 Phase 3, primary
certolizumab pegol31.6%25.4%+6.2wk 6 · n 215NCT00552058 Phase 3, primary
duvakitug54.3%41.3%+13900 mg · wk 14 · n 46NCT05499130 Phase 2b, secondary
filgotinib39.3%22.2%+17.1200 mg · wk 10 · n 28NCT03046056 Phase 2, secondary
infliximab47.3%34.1% (Azathioprine + Placebo)—wk 10 · n 169NCT00094458 Phase 3, secondary
mirikizumab37.7%25.1%+12.6wk 12 · n 579NCT03926130 Phase 3, secondary
ozanimod29.8%30.5%−0.7wk 12 · n 403NCT03440385 Phase 3, primary
risankizumab42%19.8%+22.2600 mg · wk 12 · n 191NCT03104413 Phase 3, primary
tofacitinib43.0%36.7%+6.410 mg BID · wk 8 · n 86NCT01393626 Phase 2, primary
upadacitinib49.5%29.1%+20.445 mg QD · wk 12 · n 350NCT03345849 Phase 3, primary
ustekinumab15.9%7.3%+8.6130 mg · wk 8 · n 245NCT01369329 Phase 3, secondary
vedolizumab14.5%6.8%+7.7wk 6 · n 220NCT00783692 Phase 3, primary

Drugs checked with no result here: 9 trial running, 57 not reported, 2 not posted.

Endoscopic response (induction)

Endoscopic response (induction) in Crohn's Disease: 4 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
duvakitug47.8%13%+34.8900 mg · wk 14 · n 46NCT05499130 Phase 2b, primary
mirikizumab32.5%12.6%+19.9wk 12 · n 579NCT03926130 Phase 3, secondary
risankizumab28.8%11.2%+17.6600 mg · wk 12 · n 191NCT03104413 Phase 3, primary
upadacitinib45.5%13.1%+32.445 mg QD · wk 12 · n 350NCT03345849 Phase 3, primary

Drugs checked with no result here: 11 trial running, 5 not posted, 60 not reported.

Clinical remission (maintenance)

Clinical remission (maintenance) in Crohn's Disease: 9 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
adalimumab38.1%9.1%+2940 mg Eow · wk 52 · n 21NCT00445432 Phase 2/3, primary
adalimumab-adbm (Cyltezo)68.6%76.2% (Humira EU)—wk 24 · n 68NCT02871635 Phase 3, secondary
certolizumab pegol37.5%35%+2.5wk 34 · n 16NCT00356408 Phase 3, secondary
filgotinib42.9%28.3%+14.6200 mg · wk 58 · n 112NCT02914561 Phase 3, primary
infliximab66%54.7% (Azathioprine + Placebo)—wk 50 · n 97NCT00094458 Phase 3, secondary
mirikizumab54.1%19.6%+34.5wk 52 · n 579NCT03926130 Phase 3, secondary
tofacitinib41.9%28.6%+13.310 mg BID · wk 26 · n 43NCT01393899 Phase 2, secondary
ustekinumab53.1%35.9%+17.290 mg SC q8w · wk 44 · n 128NCT01369355 Phase 3, primary
vedolizumab48%34.3%+13.7108 mg SC · wk 52 · n 275NCT02611817 Phase 3, primary

Drugs checked with no result here: 12 trial running, 57 not reported, 2 not posted.

Endoscopic response (maintenance)

Endoscopic response (maintenance) in Crohn's Disease: 3 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
filgotinib30.4%9.4%+21200 mg · wk 58 · n 112NCT02914561 Phase 3, primary
mirikizumab48.4%9%+39.4wk 52 · n 579NCT03926130 Phase 3, secondary
ustekinumab23.5%16% (Ustekinumab)—q4w · wk 48 · n 51NCT04245215 Phase 3, secondary

Drugs checked with no result here: 14 trial running, 4 not posted, 59 not reported.

  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 80 approved or late-stage drugs with a featured trial in Crohn's Disease were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.